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Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disabling disease
characterized by unexplained incapacitating fatigue, accompanied by variable
multi-systemic symptoms. ME/CFS causes a significant personal and public health
burden, and urgently requires the coordination of research efforts to investigate its
etiology and pathophysiology and to develop and validate sensitive and specific
biomarkers to confirm diagnosis. This narrative paper describes how people with
ME/CFS, together with a multidisciplinary team of researchers, have established the
UK ME/CFS Biobank (UKMEB), a unique research infrastructure specifically designed
to expedite biomedical research into ME/CFS. We describe the journey that led to
its conceptualization and operation, and how the resource has served as a model
disease-specific biobank, aggregating human biospecimens alongside comprehensive
health information on participants. The UKMEB currently has data and samples from 600
donors including people with ME/CFS and a comparison group with multiple sclerosis
and healthy controls. A longitudinal sub-cohort has been established of participants
having follow-up assessments at multiple time-points. As an open resource for quality
and ethical research into ME/CFS, biological samples and data have not only been
analyzed within our research team but have also been shared with researchers across
Europe, America and the Middle East. We continue to encourage researchers from
academic and commercial sectors to access the UKMEB. Major steps have been taken
and challenges remain; these include sustainability and expansion, and harmonization of
processes to facilitate integration with other bioresources and databanks internationally.
Keywords: ME/CFS, research infrastructure, biobank, partnership, patient engagement PE
INTRODUCTION
This paper describes a journey, beginning with extensive conversations between medical
researchers, people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), their
carers, ME charities, and a multidisciplinary team of professional experts, and continuing with the
establishment and operation of the UKME/CFS Biobank (UKMEB) (1).
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The UKMEB is, to our knowledge, the only biorepository in
the United Kingdom, and one of few worldwide, dedicated to
the study of ME/CFS. Such disease-specific biobanks hold high
quality anonymised samples enriched by comprehensive datasets
with information about the donors, all appropriately and securely
stored until required for use in research. We delineate the
progress our team have achieved and the remaining challenges
that need to be addressed in order for the UKMEB to be able to
realize its full potential.
Using a combination of qualitative methods (1, 2), we
carried out extensive consultations with people with ME/CFS
(PWME), a multidisciplinary group of experts in tissue banking,
ethics and law, and clinicians and researchers with expertise
in ME/CFS. The resultant unanimous view was that a disease-
specific biobank would be a highly desirable way to enhance
biomedical research in ME/CFS. In the safety of the participatory
environment, PWME were able to express their justifiable
concern that, in the absence of biomarkers, their illness is
frequently dismissed as trivial or psychosocial (3–5), even
though many are more debilitated by their disease than people
with other chronic and severe diseases such as cancer and
rheumatoid arthritis (6, 7). PWME told us that they would
be willing to donate tissues, including blood, oral fluid and
urine for research, as part of a process centered on the needs
and priorities of those with ME/CFS (1). They believed that
an ME/CFS Biobank would be feasible and cost-effective, and
that its implementation would strengthen and further ME/CFS
research.
FEATURES OF THE UKMEB PROTOCOL
The input from both PWME and the multidisciplinary group
led to the development of a robust protocol, incorporating
recommendations, which included:
• Comprehensive patient phenotyping and depth of any
information provided by biobank donors;
• The use of rigorous standards for data and sample collection,
processing, and storage;
• The inclusion of patients who are “severely affected, including
those that are bed-ridden” (quote from a person with ME/CFS
during focus-groups discussions); and
• The inclusion of control or comparison group(s).
Participants of the UKMEB were recruited through the National
Health Services (NHS) general practices (GPs) and specialist
services with support from the clinical and research networks
of the National Institute of Health Research (NIHR). Those
with ME/CFS required a previous medical diagnosis of ME/CFS
and those with MS a previous diagnosis given by a NHS
consultant. Healthy controls were also recruited through GP
practices, other participants’ contacts and higher education
institutes.
The UKMEB received ethical approval from the London
School of Hygiene & Tropical Medicine (LSHTM) Ethics
Committee (ref. 6123), the National Research Ethics Service
(NRES) London-Bloomsbury Research Ethics Committee (REC;
ref. 11/LO/1760, IRAS ID: 77765), and the NHS Research
Governance and Developments Offices (R&D), which oversee
the recruitment of research participants from government health
services. LSHTM and UCL-RFH Biobank hold Human Tissue
Act licenses—HTA-12066 and HTA-11016, respectively.
Possible barriers to participation in a potential biobank
resource were also discussed, and were mostly related to concerns
with the misuse of the resource:
“if you’re trying to get as much people as you can, they are afraid
of what you’re going to do, whether the government would get a
hold of it, whether the insurance companies could use it, or whether
benefit agencies would use it” (quote from a person with ME/CFS
during focus-groups discussions).
It was agreed that such misuse could be avoided by the
implementation of robust ethical standards, which is reflected
in the UKMEB mission statement that reads—“The UKMEB is
to conduct high quality, ethical investigations into ME/CFS and
to create an open resource to enable translational research for the
clinical and biomedical understanding of the illness while fostering
cooperation and collaboration between researchers and thereby
enhancing the opportunity for breakthrough discoveries.”
Other key aspects of the final protocol informed by PWME
together with experts include:
Control Groups
In addition to ME/CFS cases of different severities, we have
recruited donors who serve as healthy controls; these individuals
are grouped matched by age and sex and have no history of
fatigue or fatigue-causing diseases, including cancer, hepatitis
B or C, major depression or psychiatric illness, obesity, and
diabetes.We also recruited people withMultiple Sclerosis (MS)—
who often experience chronic fatigue as a major symptom—for a
disease comparison group.
Clinical Phenotyping
Detailed questioning of potential participants with ME/CFS
enables their disease to be classified according to different
case definitions. To be accepted as a participant with ME/CFS,
potential donors must meet either the Canadian Consensus
Criteria (8) or CDC-1994 criteria (9); many fulfill both. The
assessment process for compliance with study criteria includes
baseline questionnaires about symptoms, a clinical assessment
performed by a clinical member of the research team, and
urinalysis screening and baseline blood tests, which are used to
exclude alternative diagnoses.
In some association studies bias can be minimized by using
samples from participants who meet at least both sets of criteria
(10).
Extensive data collection together with the results of
molecular analyses facilitates disease stratification, which aims
to identify subgroups of patients with distinct mechanisms
of disease (or other features), which may require quite
different treatment approaches. Initial sub-grouping can be
based on readily available variables obtained from patient
questionnaires, examples of which include age, sex, type of
Frontiers in Neurology | www.frontiersin.org 2 December 2018 | Volume 9 | Article 1026
Lacerda et al. The UK ME/CFS Biobank Journey
disease onset (e.g., sudden or gradual; post-infection or not), co-
morbidities, clinical severity, and disease phase and duration.
The “Participant Phenotyping Questionnaire” completed by all
UKMEB participants has been used to characterize individuals
according to the presence and severity of seven groups of
symptoms (or symptom clusters), which are largely based on
the Canadian Consensus Criteria (8). Table 1 compares study
groups according to some of these variables, including general
indicators of disease severity and the severity of symptoms
related to each of the clusters described. For the latter, the scores
are obtained from the severity of individual symptoms, each
expressed as a value from 0 to 3; scores from each symptom
within the cluster are added together, resulting in the cluster
score, which is adjusted on a scale from 0 to 100, where “0”
represents no symptoms and “100” symptoms experienced with
maximum severity. For example, the severity of post-exertion
malaise symptoms is highest in the severely affected cases of
ME/CFS (median = 80), also high in those with mild/moderate
disease (median = 67), and modest in people with MS (median
= 27).
Inclusion of the Severely Affected
The systematic inclusion of participants with very severeME/CFS
for research purposes is, we believe, unique to the UK ME/CFS
Biobank. This patient group usually has poor access to services
and has often been excluded from research studies, not only
because they are home- or bed-bound, but also because PWME
often disengage from statutory medical services when they
encounter skepticism or when the treatment offered is of limited
value. Reaching them involves complex logistic and economic
considerations.
“Arranging to see these extremely ill participants presents its own
challenges, including the timing of appointments and the length
of time that it may take to clinically assess participants, whose
every move can take an enormous effort and for whom the process
can require days of preparation and weeks of recovery time. Any
external stimuli including touch, light and sound can exacerbate
symptoms, so strategies must be undertaken to reduce the impact
on participants. Certain clinical assessment procedures may not be
feasible and blood samples are sometimes taken with the light from
a torch in a darkened room. Nonetheless, the materials generated by
these severely affected participants could provide crucial insight into
the pathology of the disease, as they may present with exaggerated
biochemical and/or immunological changes.” (Quote from CK
(co-author) on the task of the Research Nurse)
Longitudinal Data and Samples
Through the systematic longitudinal collection of clinical data
and blood samples, it is possible to investigate associations
between clinical characteristics and changes in disease severity
over time, as well as in a range of molecular markers, e.g.,
immune and genetic expression phenotypes.
We employ several validated measures of disease severity
(11), while acknowledging the need for further development of
ME/CFS-specific outcome measures. For example, patient-based
assessments of disease impact or severity, such as the SF-36v2TM,
have been used in a variety of clinical settings and are monitored
in clinical research to add to our understanding of disease
severity, treatment outcomes, and therapeutic response (12).
Changes between baseline and follow-up assessment-points can
be compared with differences in biomarkers to help characterize
clinical phenotypes. By using the suggested minimally important
difference (MID) in SF-36v2TM normalized scores, e.g., of ±4.7
points for the Physical Component Summary (PCS) and ±5.8
points for the Mental Component Summary (MCS), it is possible
to ascertain improvement or worsening of scores with 95%
confidence (12).
Figure 1 shows that <50% of the PWME demonstrated
significant changes in these indicators from baseline to
subsequent assessment. If there are persistent trends toward
improvement or deterioration in repeated assessments, thesemay
reflect disease progress or pathophysiological changes that may
differ from those related to a fluctuation of symptoms.
UKMEB POTENTIAL: CURRENT STATUS
AND ENHANCING RESEARCH
Resource Sharing
Between 2013 and 2017, biological samples alongside
questionnaire and clinical data were collected from 600
participants (including 350 PWME), forming an extensive
dataset. A second round of data collection took place 6–12
months after recruitment, with 140 PWME and 130 controls
followed-up after baseline. From 2018 to 2020, a further 650
participants are planned to be seen at least once and a subset of
110 PWME to be seen on at least four occasions (and up to six),
creating robust data that enables powerful longitudinal analyses.
The UKMEB currently holds over 35,000 aliquots of blood
derivatives. Blood taken from each participant is processed to
produce seven different types appropriate to the expected end
use of the samples and suitable for a wide range of assays. After
fractioning, an average of 46 aliquots is stored following each
participant-contact as follows: serum (n= 10), plasma (processed
from sodium heparin vacutainers n = 7, and from EDTA
vacutainers n= 3), peripheral blood mononuclear cells (PBMCs)
(processed from sodium heparin vacutainers n = 17, and from
EDTA vacutainers n= 3), whole blood (n= 4), and RNA (n= 1–
2). Additionally, for each participant contact, the UKMEB stores
red blood cells/granulocyte pellet (n = 1), and PAXGENE tubes
(n= 1–2).
Some of these are available to researchers at the LSHTM,
the home of the UKMEB team, contributing to their ongoing
projects in immunology, genomics, transcriptomics, virology,
and clinical research. The rest of the samples are stored for
the use of researchers from the academic and commercial
sectors in biomedical research, following an established protocol
for the release of samples, subject to ethical review and an
approved, peer-reviewed application https://cureme.lshtm.ac.uk/
researchers/accessing-the-biobank/.
Biobanks facilitate the sharing of biological samples and
data in a cost- and time-effective way over many years (13).
The cost savings to researchers vary depending on multiple
factors, such as the type and size of the study, but have
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TABLE 1 | Characteristics of cases (both mild/moderately affected and severely affected) and controls (healthy controls and MS diseased controls) within UKMEB, with
cases of ME/CFS defined using a combination of three diagnostic criteria: CDC-1994, CCC, and IOM.
Characteristic Cases Controls
CDC94+CCC+IOM
N = 232(38)
Mild/ moderately
affected
†
N = 177(76)
Severely
Affected‡
N=55(24)
HC
N = 153(25)
MS N = 90
(15)
Age, in years Median(IQR) 48 (38,56) 48 (40,57) 50 (37,55) 47 (35,56) 55 (48,60)
Sex, female N(%) 155 (76) 114 (76) 41 (76) 84 (62) 59 (78)
Disease duration
(years)
Median(IQR) 12 (6, 18) 10 (5, 17) 16 (9, 22) - 12 (8, 20)
Disease Severity* Fatigue severity scale Median(IQR) 6.7 (6.3,7.0) 6.7 (6.2,7.0) 6.7 (6.3,6.9) 2.0 (1.6,2.8) 5.7 (4.1,6.4)
Fatigue analog scale Median(IQR) 7.3 (6.2,8.2) 6.9 (6.1,7.8) 7.6 (6.6,8.3) 1.1 (0.2,2.1) 6.2 (3.6,7.2)
Pain analog scale Median(IQR) 5.8 (3.2,7.2) 5.8 (3.1,7.1) 5.9 (3.2,7.4) 0.5 (0.0,1.2) 2.8 (0.7,6.2)
PCS Median(IQR) 26 (20,33) 28 (24,36) 20 (16, 22) 58 (56,60) 38 (29,48)
MCS Median(IQR) 41 (33,49) 40 (32,46) 46 (38,51) 55 (49,58) 48 (39,55)
Severity score for
clusters of
symptoms**
Post-exertional Malaise Median(IQR) 67 (53,67) 67 (53,67) 80 (73,80) 0.0 (0.0,0.0) 27 (13,53)
Pain Median(IQR) 47 (27,67) 53 (27,67) 47 (27,80) 3.5 (0.0,10) 20 (7,40)
Neurological/cognitive
symptoms
Median(IQR) 50 (33,67) 43 (31,60) 62 (50,83) 0.0 (0.0,5.0) 36 (21,52)
Autonomic Median(IQR) 40 (23,57) 37 (22,50) 52 (40,77) 0.0 (0.0,3.0) 19 (10,32)
Neuroendocrine Median(IQR) 47 (33,67) 47 (27,60) 60 (47,80) 0.0 (0.0,0.0) 33 (20,53)
Sleep dysfunction Median(IQR) 83 (67,100) 67 (67,100) 100 (67,100) 0.0 (0.0,33) 50 (25,67)
Immune Median(IQR) 33 (22,50) 33 (22,50) 33 (22,56) 0.0 (0.0,6.0) 6.0 (0.0,11)
Disease onset Suddenly N(%) 91 (46) 60 (42) 31 (58) - 30 (39)
Over time N(%) 80 (41) 63 (44) 17 (32) - 31 (41)
Not sure N(%) 25 (13) 20 (14) 5 (9) - 15 (20)
CDC94: Centres for Disease Control-1994; CCC: Canadian Consensus Criteria; IOM: Institute of Medicine; HC: healthy controls; MS: Multiple Sclerosis; PCS: Summary Physical
Component Score from SF-36; MCS: Summary Mental Component Score from SF-36v2TM. *For Fatigue Severity and Analog Scales and Pain Analog Scales; values vary from 0 to
10, where 10 indicates maximum severity. Normalized Physical and Mental Component summaries are presented; higher values represent better health status/quality of life.**Severity
of symptoms within the cluster; values range from 0 (no symptom) to 100 (most severe symptoms).
†
Mild/moderately affected defined as participants who are ambulatory. ‡Severely
affected defined as participants who are house- or bed-bound.
been estimated to provide a 90% saving (14). These are in
addition to significant time savings in selection, recruitment,
and data and sample acquisition. This centralization of data and
samples creates economies of scale, enabling and accelerating
research.
In May 2016, the UKMEB opened to external researchers,
who are able to apply for access to samples and data.
Academic, non-commercial, and commercial researchers have
since been eligible to apply to use the Biobank, when the
proposed study has a sound scientific rationale and all ethical
permissions are in place. Priority of research applications is
given to studies testing or generating new hypotheses on
the pathophysiology of ME/CFS, improving diagnosis and
phenotyping, or in basic science (e.g., pharmacological in
vitro studies potentially leading to clinical trials on therapeutic
approaches).
The procedures for this access to data and samples, approved
by the UKMEB Biobank Steering Committee, a multidisciplinary
body comprising PWME, carers, researchers, and clinicians,
include: (i) a review of outline proposals by Steering Committee
members, (ii) a peer review of full proposals, (iii) ethical approval
by the UCL-RFH ethics committee (BERC), and (iv) Data
and/or Material Transfer Agreements (DTA and/or MTA). All
proposals must also receive ethical approval from their local
ethics committee.
Since the UK ME/CFS Biobank opened its doors, it has
received applications from institutions in the UK and other
European countries, North and South America, and the
Middle East - encompassing diverse research topics including
immunology, metabolomics, genetics, transcriptomics, and
microbiology.
Sustainability
The UKMEB has relied on support from charities and has
benefited from research grants, which have helped with
recruitment, sample acquisition, data entry, and storage. This
funding has supported core infrastructure, but only for the time
period in which projects were taking place. To survive and
thrive in the long term, plans were made for the continuing
storage of samples and data, and particularly for the release of
samples to external researchers. This necessitated the creation
of a UKMEB Business Plan, which evolved with input from the
Steering Committee.
A fee structure was calculated and agreed upon - fees are
requested from biobank users on a cost-reimbursement basis, so
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FIGURE 1 | Longitudinal changes in SF-36v2TM Component Summary scores, in people with ME/CFS who participate in the UK ME/CFS Biobank, between baseline
and first follow-up*. *First follow up occurred between 6 and 12 months from baseline, Y-axis represents difference in scores between first follow-up assessment and
baseline assessment; positive values indicate scores are higher at follow-up assessment, and therefore represent improvement. PCS, Normalized Physical
Component Summary scores from SF-36v2TM; MCS, Normalized Mental Component Summary score from SF-36v2TM.
that sample stores can be replenished in the future and, where
possible, additional recruitment or follow-up can be facilitated.
The long-term sustainability of the UKMEB relies upon
multiple income streams, minimizing the risk of being
exposed overly to any one source of funding. In financial
year August 2015—July 2016, charity funding formed
around 90% of gross revenue, but in financial year August
2017–July 2018, that had reduced to around 60%, with
donations and cost recovery charged forming the remaining
of 40% of total gross. The key elements of future UKMEB
income are (i) fees for using the samples and data, (ii)
philanthropic donations, (iii) crowdfunding and regular
giving, and (iv) research grant support, which have to coexist
to ensure long-term sustainability (14, 15). The opening
of other income streams in the past financial year has
shown that it is possible to move to a multi-source revenue
system in biobanking, once appropriate start-up capital has
been invested to enable fundraising and awareness-raising
efforts.
Engagement With the Community
Social media, websites and web fora play a fundamental role in
the lives of many with ME/CFS, facilitating social connection
with others in the community as well as with researchers and
charities, particularly when the physical demands of face-to-face
interaction are not feasible. For PWME, online platforms can be
one of the few places where their voices are heard and can be an
invaluable resource in encouraging ongoing partnership between
the ME/CFS community and researchers.
Engagement with these communities remains a key pillar of
the UKMEB’s strategy. We endeavor to remain transparent in
our research objectives and stay engaged with PWME online, so
that the communities we serve are actively involved in how we
progress. In addition, we strive to be accountable to our donors
by sharing whatever news and findings we can via social media
and via our website.
This renewed focus on public engagement (since August
2017) has coincided with an increase in our donation
income, as well as an increase in applications received
from researchers wanting to use our resource. While
any concrete causal relationship is difficult to prove, we
feel that an active and open public engagement strategy
supports several of the income streams delineated above,
and helps contribute to the UKMEB’s sustainability efforts,
while also building trust between the research team and the
community.
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FINAL REMARKS—WHERE THIS
JOURNEY IS HEADING?
Biobanks are recognized as key to biomedical research; and
their numbers have been increasing globally, as human bio-
specimens, combined with health information on their donors,
provide a critical resource for biomedical research (16). Disease-
specific biobanks, in particular, are useful for addressing
conditions such as ME/CFS, where there remain important
unanswered questions around causes, diagnosis, pathophysiology
and treatment (17, 18). We believe that the UKMEB can be used
as a model for others contemplating developing bio-resources
in the field of ME/CFS; or indeed for other specific diseases,
one that incorporates participatory approaches, partnership, time
and cost-effectiveness, and sustainability into the design and
implementation.
The integration of the UKMEB with other ME/CFS-specific
biobanks could involve the sharing of protocols or at least an
agreement to collect some common data and samples, and will
be essential for accelerating much-needed ME/CFS research.
Such research will likely include the investigation of potential
biomarkers, transcriptomics, metabolomics, genomic and genetic
studies; biobanks may also be accessed by those seeking to
improve diagnosis and treatment, and undertake validation
studies.
The poor recognition of and stigma that surrounds the disease
are still present, and the wider needs of PWME in relation to
healthcare, social, occupational and education support remain
largely unmet (3). We have previously described the perceived
needs of PWME, and some aspects of the care they receive
(19). In this article, we focused on how the UKMEB evolved
as we sought, in partnership, to help address some of these
needs and to advance research into the disease. We described a
journey that evolved from conversations with people with ME
to an established resource facilitating biomedical research into
ME/CFS locally and internationally. The journey has only just
begun.
The enthusiasm from the ME/CFS community and from
participants, including those with MS and healthy controls, has
contributed to the success of a project developed while keeping
the needs of patients and the research community in mind. With
follow-up rates presently over 90% and an increasing number
of external researchers using data and samples, the UKMEB is
successfully delivering. However, the real benefits will only be felt
when the results of research are effectively translated into better
health for PWME.
There is no doubt that ME/CFS research can further be
accelerated through the integration of bio-resources and the
facilitation of consistent data collection globally. We are actively
discussing and engaging with other bio-resources globally. The
Common Data Elements project developed by the National
Institute of Neurological Disorders and Stroke (20), is one
example of an initiative aimed at data harmonization and
integration in ME/CFS research. Another is the European
Network onME/CFS (EUROMENE), which combines resources,
technologies, and expertise from over 20 European countries in
a multidisciplinary approach to optimize knowledge production
in the field. The harmonization of ME/CFS related data and bio-
resources across the continent is one of the objectives of the
network (21).
Improved research is only one of many challenges that needs
addressing in the field, and we hope that our experiences
presented here represent some contribution to this effort. It
is only with substantial increases in research and research-
infrastructure funding, and significant improvement in services
for those with ME/CFS, that the individual journeys of PWME
will be improved.
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